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Objectives. This study was performed to determine predictors of
in-stent restenosis from a high volume, single-center practice.
Background. Intracoronary stents have been shown to reduce
the restenosis rate as compared with balloon angioplasty, but
in-stent restenosis continues to be an important clinical problem.
Methods. Between April 1993 and March 1997, 1,706 patients
with 2,343 lesions were treated with a variety of intracoronary
stents. The majority of stents were placed with high pressure
balloon inflations and intravascular ultrasound (IVUS) guidance.
Angiographic follow-up was obtained in 1,173 patients with 1,633
lesions (70%). Clinical, angiographic and IVUS variables were
prospectively recorded and analyzed by univariate and multivar-
iate models for the ability to predict the occurrence of in-stent
restenosis defined as a diameter stenosis >250%.
Results. In-stent restenosis was angiographically documented
in 282 patients with 409 lesions (25%). The restenosis group had
a significantly longer total stent length, smaller reference lumen
diameter, smaller final minimal lumen diameter (MLD) by an-
giography and smaller stent lumen cross-sectional area (CSA) by
IVUS. In lesions where IVUS guidance was used, the restenosis
rate was 24% as compared with 29% if IVUS was not used (p <
0.05). By multivariate logistic regression analysis, longer total
stent length, smaller reference lumen diameter and smaller final
MLD were strong predictors of in-stent restenosis. In lesions with
IVUS guidance, IVUS stent lumen CSA was a better independent
predictor than the angiographic measurements.
Conclusions. Achieving an optimal stent lumen CSA by using
IVUS guidance during the procedure and minimizing the total
stent length may reduce in-stent restenosis.
(J Am Coll Cardiol 1998;32:1630–5)
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Intracoronary stents have been shown to reduce the rate of
restenosis as compared with balloon angioplasty (1–4), but
in-stent restenosis continues to be an important clinical prob-
lem (5–9). It has been reported that final minimal lumen
diameter (MLD) by angiography is the best inverse predictor
of restenosis (10); however, Nakamura et al. (11) showed that
angiography overestimated the adequacy of acute stent expan-
sion and the size of post-stent lumen diameters. Intravascular
ultrasound (IVUS) permits detailed cross-sectional imaging of
the coronary arteries (12) and has been used to optimize stent
deployment (13,14). The incremental effect of this approach on
restenosis is unclear. The purpose of the present study was to
evaluate the clinical, angiographic and ultrasound predictors of
in-stent restenosis from a single-center, large-volume experi-
ence.
Methods
Patients. Intracoronary stents were deployed in 1,706 con-
secutive patients with 2,343 lesions between April 1993 and
March 1997. Angiographic follow-up was requested in all
patients within 6 months and was obtained in 1,173 patients
(69%) with 1,633 stented lesions (70%). This group of patients
with angiographic follow-up constituted the study group. The
only patients excluded from this analysis were those with
restenosis lesions from a previous stent implantation.
Clinical, angiographic and IVUS variables were analyzed to
describe the study group and to determine predictors of
angiographic restenosis. Follow-up coronary angiography was
performed at a median of 5.1 months (range 1 to 34) after stent
implantation. Angiographic restenosis was defined as $50%
diameter reduction of the mean proximal and distal reference
lumens. Patients were classified into two groups: 891 patients
(1,224 lesions) without restenosis and 282 patients (409 le-
sions) with restenosis.
Stent implantation procedure. Intracoronary stenting was
performed by using techniques that have been previously
described (13). The Palmaz-Schatz coronary stent (Cordis,
Johnson & Johnson Company) was the stent most commonly
used (46%). Other stents were used in 45% of lesions, and a
combination of stents was used in 9% of lesions. After
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intracoronary stent implantation, angiographic optimization
was performed by using high pressure balloon dilations
(.14 atm) to achieve a satisfactory angiographic result with
,20% residual stenosis by visual estimate. The mean final
balloon pressure was 16.1 6 3.2 atm. After the angiographic
result was considered acceptable, such that the procedure
would ordinarily be terminated, IVUS was performed. IVUS
imaging was obtained in 921 patients (79%) with 1,248 lesions
(76%). Alternatively, IVUS imaging was obtained before any
intervention or after the first predilation in 218 lesions (13%).
The measured IVUS lumen area was used to choose the
balloon for expanding the stent. If IVUS imaging was not
available, a balloon diameter was chosen that was $0.5 mm
larger than the angiographic reference lumen diameter. The
mean balloon/artery ratio was 1.2 6 0.2. Total stent length was
defined as the sum of the length of all stents implanted for each
lesion.
Quantitative coronary angiographic analysis was performed
using digital calipers by experienced angiographers not in-
volved in the stent procedure. MLD, reference lumen diameter
and percent diameter stenosis (%DS) before and after stent
implantation and at follow-up were measured.
IVUS studies were obtained as previously described (13).
The lumen cross-sectional area (CSA) was measured at the
proximal and distal reference sites and at the most narrowed
point within the stent.
Statistical analysis. Statistical analysis was performed on a
Power Macintosh 8500 with commercially available software
programs (Statview 4.5, Abacus Concept Inc., and JMP 3.1,
SAS Institute Inc.). Data were expressed as the mean value 6
SD. Differences between groups were evaluated by the chi-
square test or the Fisher exact test for categoric variables and
the Student t test for continuous variables. P values ,0.05 were
considered significant.
Univariate logistic regression analysis was used to select the
clinical, angiographic or IVUS predictors of angiographic
restenosis. Univariate predictors of angiographic restenosis
with a p value ,0.05 were entered into a multivariate logistic
model. A backward elimination was used to select independent
predictors. A p value ,0.05 was required for all variables to be
included in the final multivariate stepwise model. The odds
ratios (OR) and 95% confidence intervals are presented in the
tables for the final multivariate model. The OR was calculated
as
OR 5 e~b*x!
where b is the estimate and x equals the unit measurement for
continuous variables. For MLD and reference lumen diameter,
the unit of measurement was taken as 1 mm; for stent length it
was 10 mm; for CSA it was 1 mm2; and for age it was 10 years.
An OR .1 means an increase in the predicted risk of
restenosis for the variable listed.
Results
Comparison of patients with and without restenosis. In-
stent restenosis was angiographically documented in 282 pa-
tients (24%) with 409 lesions (25%). As shown in Table 1, the
restenosis group had older patients and had patients with a
greater frequency of hypercholesterolemia, diabetes and pre-
vious coronary artery bypass graft surgery. The restenosis
group also had a higher incidence of saphenous vein grafts,
type C lesions, dissection and multiple stents and had a longer
total stent length. Figure 1 demonstrates the correlation
between the total stent length and in-stent restenosis rate.
Palmaz-Schatz stents and IVUS guidance were used more
frequently in the no-restenosis group.
Angiographic analysis. The restenosis group had a longer
lesion length, a smaller angiographic reference lumen diame-
ter, a smaller final MLD and a higher %DS after the stent
procedure (Table 2). There was a significant inverse correla-
tion between the in-stent restenosis rate and the angiographic
reference lumen diameter (Fig. 2) or the final MLD (Fig. 3).
IVUS analysis. The restenosis group had a smaller final
stent lumen CSA that occurred in smaller arteries with a
smaller proximal or distal reference lumen CSA (Table 2).
Figure 4 demonstrates the inverse correlation between stent
lumen CSA and in-stent restenosis rate.
Comparison between IVUS and no-IVUS guidance. To
achieve an optimal result, additional inflations were performed
in 420 (34%) of 1,248 lesions with IVUS guidance, and
additional stents were implanted in 241 lesions (19%). The
lesions with IVUS guidance had a significantly larger final
MLD (3.2 6 0.6 vs. 3.0 6 0.5 mm, p , 0.0001) and a smaller
final %DS (20.3 6 13.2% vs. 4.3 6 12.0%, p , 0.0001), as well
as a larger acute gain (2.2 6 0.7 vs. 2.0 6 0.6 mm, p , 0.0001),
as compared with lesions without IVUS guidance. In addition,
the lesions with IVUS guidance had a significantly lower
in-stent restenosis rate (24% vs. 29%, p 5 0.03).
Multivariate logistic regression analysis. Eleven clinical
variables (age, male gender, hypercholesterolemia, active
smoking, diabetes, hypertension, previous myocardial infarc-
tion, previous bypass surgery, previous coronary angioplasty,
unstable angina and indication for stenting), five procedural
variables (IVUS guidance, Palmaz-Schatz stent, single stent,
number of stents per lesion, and total stent length), and five
angiographic variables (lesion type, lesion length, reference
lumen diameter, pre MLD and final MLD) were assessed by
univariate logistic regression analysis to determine their cor-
relation with angiographic restenosis. As shown in Table 3,
there were 13 univariate predictors of restenosis that were
entered into a multivariate logistic regression model for
Abbreviations and Acronyms
CSA 5 cross-sectional area
%DS 5 percent diameter stenosis
IVUS 5 intravascular ultrasound
MLD 5 minimal lumen diameter
OR 5 odds ratio
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the binomial variable of angiographic restenosis. In-stent re-
stenosis was predicted independently by six variables (Table 3,
right). Of these variables, a longer total stent length, previous
bypass surgery, patient age and diabetes were variables that
increased the risk of restenosis. A larger angiographic refer-
ence lumen diameter and a larger final MLD were variables
that decreased the risk of restenosis. The best predictors of
restenosis were total stent length and angiographic reference
lumen diameter. The OR indicates that the predicted risk of
restenosis increases 26% for every 10-mm increase in total
stent length, and restenosis risk decreases 53% for ever 1-mm
increase in reference lumen diameter. The use of IVUS
guidance did not reach statistical significance in the multivar-
iate model.
To assess the predictors of in-stent restenosis in lesions
where IVUS measurements were obtained, stent lumen CSA
by IVUS was entered into the multivariate model. As shown in
Table 4,, IVUS stent lumen CSA and total stent length were
the best predictors of in-stent restenosis in the patients in
whom IVUS was performed. The OR indicates that the
predicted risk of restenosis decreases 19% for ever 1-mm2
increase in stent lumen CSA. When IVUS measurements were
entered into the multivariate model, final MLD by angiogra-
phy was no longer an independent predictor of restenosis.
Because the chance of restenosis of different stents within
the same patient may not be independent, a separate logistic
regression model was performed using the patient as the unit
of analysis. In this model the independent predictors were the
same as those in the per lesion analysis: total stent length (OR
1.34/10 mm), final MLD (OR 0.54/1 mm), diabetes (OR 1.33),
reference diameter (OR 0.61/1 mm), previous bypass surgery
(OR 1.32) and age (OR 1.17/10 years).
Table 2. Angiographic and Intravascular Ultrasound Measurements
in the Restenosis or No Restenosis Groups
No
Restenosis Restenosis p Value
Angiography
No. of lesions 1224 409
Lesion length (mm) 11 6 7 12 6 8 0.0008
Reference diameter (mm) 3.1 6 0.5 2.8 6 0.5 , 0.0001
Pre MLD (mm) 0.9 6 0.6 0.8 6 0.5 0.004
Final MLD (mm) 3.2 6 0.6 2.9 6 0.5 , 0.0001
Pre %DS 70 6 17 70 6 17 NS
Final %DS 0.0 6 13 3.1 6 14 , 0.0001
Acute gain* (mm) 2.2 6 0.7 2.0 6 0.7 , 0.0001
Intravascular ultrasound
No. of lesions 952 296
Proximal reference L-CSA (mm2) 9.4 6 3.4 8.1 6 2.7 , 0.0001
Distal reference L-CSA (mm2) 7.5 6 3.2 6.1 6 2.3 , 0.0001
Stent L-CSA (mm2) 8.0 6 2.6 6.5 6 2.1 , 0.0001
*Acute gain 5 final MLD 2 beginning MLD. Data are presented as the
mean value 6 SD. %DS 5 percent diameter stenosis; L-CSA 5 lumen
cross-sectional area; MLD 5 minimal lumen diameter.
Table 1. Clinical, Angiographic and Procedural Characteristics in
the Restenosis and No Restenosis Groups
No Restenosis
Group
Restenosis
Group p Value
No. of patients 891 282
No. of lesions 1,224 409
Age (years) 58 6 9 59 6 10 0.02
Male 795 (89%) 240 (85%) NS
Risk factors
Hypercholesterolemia 490 (55%) 176 (62%) 0.038
Active smoker 308 (35%) 74 (26%) 0.008
Diabetes 100 (11%) 52 (18%) 0.002
Hypertension 366 (41%) 118 (42%) NS
Previous myocardial infarction 489 (55%) 147 (52%) NS
Previous angioplasty 86 (10%) 33 (12%) NS
Previous CABG 83 (9%) 41 (15%) 0.017
Unstable angina 251 (29%) 90 (32%) NS
Follow-up duration (months) 5.5 6 2.4 5.3 6 2.9 NS
Treated vessels
LAD 611 (50%) 185 (45%) NS
LCx 225 (18%) 93 (23%) NS
RCA 339 (28%) 106 (26%) NS
LMCA 20 (2%) 3 (1%) NS
SVG 29 (2%) 22 (5%) 0.002
Modified AHA/ACC lesion types
A 53 (4%) 14 (4%) NS
B1 382 (32%) 97 (24%) 0.004
B2 515 (43%) 169 (42%) NS
C 247 (21%) 121 (30%) , 0.0001
Chronic occlusion 114 (9%) 43 (11%) NS
Dissection 63 (5%) 39 (10%) 0.002
Ostial lesion 85 (7%) 34 (8%) NS
Bifurcation 272 (23%) 107 (27%) NS
Restenotic lesion 68 (6%) 25 (6%) NS
No. of stents per lesion 1.4 6 0.8 1.6 6 1.0 , 0.0001
1 stent 853 (70%) 243 (60%) 0.0001
2 stents 252 (20%) 99 (24%) NS
$3 stents 119 (10%) 67 (16%) 0.0002
Total stent length (mm) 24 6 15 31 6 19 , 0.0001
Maximal inflation pressure (atm) 16 6 3 16 6 3 NS
Palmaz-Schatz stent 617 (54%) 135 (38%) , 0.0001
IVUS guidance 952 (78%) 296 (72%) 0.026
Data are presented as the mean value 6 SD or number (%) of patients or
lesions. CABG 5 coronary artery bypass graft surgery; IVUS 5 intravascular
ultrasound; LAD 5 left anterior descending coronary artery; LCx 5 left
circumflex coronary artery; LMCA 5 left main coronary artery; RCA 5 right
coronary artery; SVG 5 saphenous vein graft.
Figure 1. Effect of total stent length on in-stent restenosis rate (p ,
0.0001). n 5 total number of patients at risk per category.
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Discussion
Comparison with other studies. Klugherz et al. (15) re-
ported that predictors of clinical events 3 years after Palmaz-
Schatz stenting included diabetes, higher angina score at
follow-up, smaller stent deployment balloon size and greater
number of stents implanted. Haude et al. (16) and Ellis et al.
(17) reported that multiple stents were an important predictor
of angiographic restenosis. Carrozza et al. (18) reported that
diabetes, small postprocedure lumen diameter and stenting of
the left anterior descending coronary artery were associated
with higher rates of restenosis by multivariable logistic regres-
sion analysis. The numbers of patients in these studies (50 to
227 patients) were smaller and the patients were more selected
as compared with the patients in our study. Recently, Kastrati
et al. (19) reported that the strong predictors of in-stent
restenosis after Palmaz-Schatz stent implantation in 1,399
lesions were diabetes, multiple stents and smaller final MLD;
however, they did not analyze IVUS measurements or total
stent length.
Length of stents. A frequent finding in these previous
studies is that in-stent restenosis is more common with multi-
ple stents (16,17). Because we used a variety of stents with
different lengths, we analyzed total stent length as well as the
number of stents per lesion. By univariate logistic regression
analysis, both total stent length and the number of stents per
lesion were significant variables. By multiple logistic regression
analysis, total stent length was the strongest predictor of
restenosis, but the number of stents per lesion or lesion length
was not an independent predictor. These results suggest that
achieving an optimal result with a minimal total stent length
during the procedure may reduce in-stent restenosis.
Role of angiography and IVUS. Several studies have dem-
onstrated that the incidence of restenosis is decreased when a
larger final lumen is achieved for balloon angioplasty, directed
atherectomy or stent insertion (10,17,18,20). This prospective
analysis extends these observations. Both larger final MLD and
larger reference lumen diameter are inversely correlated with
restenosis. This combination is understandable because it is
easier to obtain a larger stented lumen area in bigger vessels.
In arteries with a reference lumen diameter $3.5 mm, the
incidence of angiographic restenosis was only 12% (Fig. 2). A
persistent problem is how to optimize the results for smaller
arteries (17,21,22) and diffuse disease.
Although angiographic guidance has been the traditional
method to assess stent deployment, we have reported that 40%
of stents with an acceptable angiographic result still required
additional dilation with larger balloon to achieve an optimal
result by IVUS (13). IVUS provided critical information
regarding the adequacy of stent deployment and reference
vessel dimensions. This information was used for determining
balloon size and whether to use a stent and for maximizing
stent expansion. The lesions with IVUS guidance had a larger
final MLD and a lower final %DS than the lesions without
IVUS guidance. These results indicate that IVUS guidance
may be useful for optimizing stent implantation. In addition,
the restenosis rate in the lesions where IVUS guidance was
used was significantly lower than in the lesions without IVUS
guidance. Because this study was not a randomized compari-
son between angiography and IVUS guidance of coronary
stenting, no definitive conclusions can be made from this
analysis. Although the binominal variable of IVUS guidance
was not an independent predictor of restenosis by multivariate
logistic regression analysis, this does not necessarily imply that
IVUS guidance does not help decrease restenosis. Because
IVUS guidance was associated with a larger final MLD, these
two variables parallel each other, and therefore IVUS guid-
ance may not appear in the model as an independent predictor
of restenosis. In lesions with IVUS guidance, stent lumen CSA
by IVUS was a better predictor of restenosis than angiographic
Figure 3. Effect of final MLD on in-stent restenosis rate (p , 0.0001).
n 5 total number of patients at risk per catetory.
Figure 4. Effect of stent lumen CSA on in-stent restenosis rate (p ,
0.001). n 5 total number of patients at risk per category.
Figure 2. Effect of angiographic reference lumen diameter on in-stent
restenosis rate (p , 0.0001). n 5 total number of patients at risk per
category.
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measurements. If the lumen CSA was $12 mm2, the angio-
graphic restenosis rate was only 7% (Fig. 4). Our interpreta-
tion is that IVUS guidance is helpful in achieving an optimal
result, which in turn may reduce in-stent restenosis.
Study limitations. Angiographic follow-up was obtained in
70% of the lesions studied during this period. Comparing the
two groups with and without follow-up angiography, the group
of patients without follow-up angiography were slightly older
(59 6 10 vs. 58 6 10 years, p , 0.01) than the group with
follow-up angiography. However, between the two groups,
there were no differences in total stent length, angiographic
reference lumen diameter, final MLD and IVUS stent lumen
CSA, which were major independent predictors of in-stent
restenosis. This suggests that the study group does not repre-
sent a biased population.
Although this was an unselected case analysis, there was no
randomized protocol for the use of different stents or IVUS
guidance. In the multivariate model, r2 5 0.1, which means
that only 10% of the variance for restenosis is predicted by
these clinical or quantitative variables. The majority of resten-
osis is not accounted for in this analysis (or by other investi-
gators’ studies). One alternative explanation may be that there
are biologic predictors that are not measurable at the present
time (23). Despite these limitations, this study is based on one
of the largest data bases available of coronary stents with
angiographic follow-up. Therefore, these observations may be
useful guidelines as predictors of in-stent restenosis, because it
is unlikely that many of these individual variables will be
studied in prospective, randomized trials.
Conclusions. This study has identified several factors that
predispose to in-stent restenosis: 1) total stent length; 2)
angiographic reference lumen diameter; 3) angiographic final
MLD; 4) previous bypass surgery; and 6) diabetes. In addition,
when IVUS guidance was used, the most important inverse
predictor of restenosis was stent lumen CSA. Achieving an
optimal stent lumen CSA with the use of IVUS guidance, with
a minimal total stent length, may reduce in-stent restenosis.
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